Royalty Pharma Monday confirmed that it is increasing its cash offer for Elan Corp., Plc (ELA.L,ELN) to $12.50 per share. The $1.00 per share net cash right has been eliminated.
The New York based company is now offering $4.6 billion for Elan's Tysabri Royalty, representing a 42 percent premium to the $3.25 billion at which Elan sold approximately half of its interest in Tysabri to Biogen.
The company believes that Elan dramatically overpaid in the Theravance Transaction by agreeing to pay $1 billion for 21 percent of selected royalties owned by Theravance when all of Theravance was trading at $3.5 billion.
The increased offer is fully financed, cash confirmed, conditional on Elan Stockholders voting against the Theravance Transaction.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.